Bertram L. Kasiske
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Bertram L. Kasiske has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Harini A. Chakkera
Department of Medicine, Hennepin County Medical Center, Minneapolis, Minnesota
2 shared publicationsD Roth
1 shared publicationDagmar Klinger
Department of Medicine, Division of Nephrology, Hennepin County Medical Center, Minneapolis, Minnesota
1 shared publicationG G Singer
1 shared publicationG M Danovitch
1 shared publicationHarini Chakkera
1 shared publication
Latest Publications
- 1 September 2001
- Published by Wolters Kluwer Health in Transplantation
- Vol. 72 (Supplement) , S5-S8
EPIDEMIOLOGY OF CARDIOVASCULAR DISEASE AFTER RENAL TRANSPLANTATION
A large proportion of late renal allograft failures are attributable to patient death with a functioning graft, with almost half of the deaths related to cardiovascular events. Using data from the Framingham Heart Study and our own renal transplant population, risk factors for cardiovascular disease in the general population, such as hypertension, hyperlipidemia, and cigarette smoking, were found to be predictive in renal transplant recipients. However, diabetes mellitus dramatically elevated the risk in renal transplantation. Also, two or more acute rejection episodes in the first year after transplantation were associated with a greater risk, whereas pretransplantation nephrectomy and higher serum albumin levels reduced the risk for ischemic heart events. Pretransplantation screening assists identification of patients who are at risk of, or who have preexisting, cardiovascular disease. Management interventions such as antihypertensives, lipid-lowering agents, antidiabetic therapy, aspirin prophylaxis, and smoking cessation have a positive impact on known risk factors for cardiovascular disease, and their use may decrease cardiovascular morbidity and mortality in renal transplant recipients.
- 1 September 2001
- Published by Wolters Kluwer Health in Transplantation
- Vol. 72 (Supplement) , S5-S8
EPIDEMIOLOGY OF CARDIOVASCULAR DISEASE AFTER RENAL TRANSPLANTATION
A large proportion of late renal allograft failures are attributable to patient death with a functioning graft, with almost half of the deaths related to cardiovascular events. Using data from the Framingham Heart Study and our own renal transplant population, risk factors for cardiovascular disease in the general population, such as hypertension, hyperlipidemia, and cigarette smoking, were found to be predictive in renal transplant recipients. However, diabetes mellitus dramatically elevated the risk in renal transplantation. Also, two or more acute rejection episodes in the first year after transplantation were associated with a greater risk, whereas pretransplantation nephrectomy and higher serum albumin levels reduced the risk for ischemic heart events. Pretransplantation screening assists identification of patients who are at risk of, or who have preexisting, cardiovascular disease. Management interventions such as antihypertensives, lipid-lowering agents, antidiabetic therapy, aspirin prophylaxis, and smoking cessation have a positive impact on known risk factors for cardiovascular disease, and their use may decrease cardiovascular morbidity and mortality in renal transplant recipients.
- Top Cited Papers
- 1 October 2000
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 11 (10) , 1910-1917
A Meta-Analysis of Immunosuppression Withdrawal Trials in Renal Transplantation
: Since the publication of previous meta-analyses of cyclosporine (CsA) and prednisone withdrawal in renal transplant recipients, several additional randomized controlled trials with longer follow-up have been reported. Currently, in nine prednisone withdrawal trials (n = 1461), the proportion of patients with acute rejection was increased by 0.14 (95% confidence interval = 0.10 to 0.17, P < 0.001). In nine prednisone withdrawal trials (n = 1899), the relative risk (RR; RR = 1.0 indicates no risk) of graft failure after withdrawal was also increased (RR = 1.40; range, 1.09 to 1.70, P = 0.012). There was no evidence of between-study heterogeneity for either acute rejection or graft failure in the prednisone withdrawal trials by a χ2 test (P > 0.05). In 10 CsA withdrawal trials (n = 1049), the proportion of patients with acute rejection was increased by 0.11 (0.07 to 0.15, P < 0.001). In 12 trials (n = 1151), the RR of graft failure after CsA withdrawal was 1.06 (95% confidence interval, 0.82 to 1.29, P = 0.646), but a χ2 test indicated that there was study heterogeneity. However, there was no evidence of heterogeneity in the six studies (n = 632) with at least 4.0 yr (5.8 ± 1.7) of follow-up (RR = 0.92; range, 0.64 to 1.20, P = 0.569) or in the seven trials (n = 962) published in peer-reviewed journals (RR = 0.95; range, 0.70 to 1.20 P = 0.682). Finally, in three trials (n = 259) that compared CsA and prednisone withdrawal, there was a nonsignificant trend for less graft failure with CsA withdrawal (RR = 0.63; range, 0.08 to 1.16, P = 0.190). Thus, unlike prednisone withdrawal, CsA withdrawal in select patients seems to impart little risk of long-term graft failure.
- 1 October 2000
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 11 (10) , 1910-1917
Top Cited PapersA Meta-Analysis of Immunosuppression Withdrawal Trials in Renal Transplantation
: Since the publication of previous meta-analyses of cyclosporine (CsA) and prednisone withdrawal in renal transplant recipients, several additional randomized controlled trials with longer follow-up have been reported. Currently, in nine prednisone withdrawal trials (n = 1461), the proportion of patients with acute rejection was increased by 0.14 (95% confidence interval = 0.10 to 0.17, P < 0.001). In nine prednisone withdrawal trials (n = 1899), the relative risk (RR; RR = 1.0 indicates no risk) of graft failure after withdrawal was also increased (RR = 1.40; range, 1.09 to 1.70, P = 0.012). There was no evidence of between-study heterogeneity for either acute rejection or graft failure in the prednisone withdrawal trials by a χ2 test (P > 0.05). In 10 CsA withdrawal trials (n = 1049), the proportion of patients with acute rejection was increased by 0.11 (0.07 to 0.15, P < 0.001). In 12 trials (n = 1151), the RR of graft failure after CsA withdrawal was 1.06 (95% confidence interval, 0.82 to 1.29, P = 0.646), but a χ2 test indicated that there was study heterogeneity. However, there was no evidence of heterogeneity in the six studies (n = 632) with at least 4.0 yr (5.8 ± 1.7) of follow-up (RR = 0.92; range, 0.64 to 1.20, P = 0.569) or in the seven trials (n = 962) published in peer-reviewed journals (RR = 0.95; range, 0.70 to 1.20 P = 0.682). Finally, in three trials (n = 259) that compared CsA and prednisone withdrawal, there was a nonsignificant trend for less graft failure with CsA withdrawal (RR = 0.63; range, 0.08 to 1.16, P = 0.190). Thus, unlike prednisone withdrawal, CsA withdrawal in select patients seems to impart little risk of long-term graft failure.
- 1 October 2000
- p. S1-86
Recommendations for the outpatient surveillance of renal transplant recipients. American Society of Transplantation.
Many complications after renal transplantation can be prevented if they are detected early. Guidelines have been developed for the prevention of diseases in the general population, but there are no comprehensive guidelines for the prevention of diseases and complications after renal transplantation. Therefore, the Clinical Practice Guidelines Committee of the American Society of Transplantation developed these guidelines to help physicians and other health care workers provide optimal care for renal transplant recipients. The guidelines are also intended to indirectly help patients receive the access to care that they need to ensure long-term allograft survival, by attempting to systematically define what that care encompasses. The guidelines are applicable to all adult and pediatric renal transplant recipients, and they cover the outpatient screening for and prevention of diseases and complications that commonly occur after renal transplantation. They do not cover the diagnosis and treatment of diseases and complications after they become manifest, and they do not cover the pretransplant evaluation of renal transplant candidates. The guidelines are comprehensive, but they do not pretend to cover every aspect of care. As much as possible, the guidelines are evidence-based, and each recommendation has been given a subjective grade to indicate the strength of evidence that supports the recommendation. It is hoped that these guidelines will provide a framework for additional discussion and research that will improve the care of renal transplant recipients.
- 1 October 2000
- p. S1-86
Recommendations for the outpatient surveillance of renal transplant recipients. American Society of Transplantation.
Many complications after renal transplantation can be prevented if they are detected early. Guidelines have been developed for the prevention of diseases in the general population, but there are no comprehensive guidelines for the prevention of diseases and complications after renal transplantation. Therefore, the Clinical Practice Guidelines Committee of the American Society of Transplantation developed these guidelines to help physicians and other health care workers provide optimal care for renal transplant recipients. The guidelines are also intended to indirectly help patients receive the access to care that they need to ensure long-term allograft survival, by attempting to systematically define what that care encompasses. The guidelines are applicable to all adult and pediatric renal transplant recipients, and they cover the outpatient screening for and prevention of diseases and complications that commonly occur after renal transplantation. They do not cover the diagnosis and treatment of diseases and complications after they become manifest, and they do not cover the pretransplant evaluation of renal transplant candidates. The guidelines are comprehensive, but they do not pretend to cover every aspect of care. As much as possible, the guidelines are evidence-based, and each recommendation has been given a subjective grade to indicate the strength of evidence that supports the recommendation. It is hoped that these guidelines will provide a framework for additional discussion and research that will improve the care of renal transplant recipients.
- Top Cited Papers
- 1 September 2000
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 11 (9) , 1735-1743
Explained and Unexplained Ischemic Heart Disease Risk after Renal Transplantation
: Whether the high incidence of ischemic heart disease (IHD) among renal transplant patients can be attributed to the same risk factors that have been identified in the general population is unclear. The risk for major IHD events occurring >1 yr after transplantation among 1124 transplant recipients was estimated by using the risk calculated from the Framingham Heart Study (FHS). The FHS risk predicted IHD (relative risk, 1.28; 95% confidence interval, 1.20 to 1.40; P < 0.001); however, the FHS risk tended to underestimate the risk of IHD for renal transplant recipients. This was largely attributable to increased risks associated with diabetes mellitus and, to a lesser extent, age and cigarette smoking for renal transplant recipients. For men, the relative risks for diabetes mellitus were 2.78 (1.73 to 4.49) and 1.53 for the transplant recipient and FHS populations, respectively; the relative risks for age (in years) were 1.06 (1.04 to 1.08) and 1.05, respectively, and those for smoking were 1.95 (1.20 to 3.19) and 1.69, respectively. For women, the relative risks for diabetes mellitus were 5.40 (2.73 to 10.66) and 1.82, respectively. There was a tendency for the risk associated with cholesterol levels to be higher for transplant recipients, compared with the FHS population, but the risks associated with high-density lipoprotein cholesterol levels and BP appeared to be comparable. Independent of these and other risk factors, the adjusted risk of IHD for the transplant recipient population has decreased. Compared with the era before 1986, transplantation between 1986 and 1992 was associated with a lower relative risk of 0.60 (0.39 to 0.92); transplantation after 1992 was associated with an even lower relative risk of 0.27 (0.11 to 0.63) for IHD. Of concern was the fact that dihydropyridine calcium channel antagonists were associated with an increased risk for IHD (relative risk, 2.26; 95% confidence interval, 1.24 to 4.12; P = 0.008), and this association was independent of other antihypertensive agents and risk factors. Therefore, although the FHS risk predicts IHD after renal transplantation, it tends to underestimate the risks, especially the risk associated with diabetes mellitus. The unexpected finding that dihydropyridine calcium channel antagonists were associated with an increased IHD risk merits further evaluation.
- 1 September 2000
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 11 (9) , 1735-1743
Top Cited PapersExplained and Unexplained Ischemic Heart Disease Risk after Renal Transplantation
: Whether the high incidence of ischemic heart disease (IHD) among renal transplant patients can be attributed to the same risk factors that have been identified in the general population is unclear. The risk for major IHD events occurring >1 yr after transplantation among 1124 transplant recipients was estimated by using the risk calculated from the Framingham Heart Study (FHS). The FHS risk predicted IHD (relative risk, 1.28; 95% confidence interval, 1.20 to 1.40; P < 0.001); however, the FHS risk tended to underestimate the risk of IHD for renal transplant recipients. This was largely attributable to increased risks associated with diabetes mellitus and, to a lesser extent, age and cigarette smoking for renal transplant recipients. For men, the relative risks for diabetes mellitus were 2.78 (1.73 to 4.49) and 1.53 for the transplant recipient and FHS populations, respectively; the relative risks for age (in years) were 1.06 (1.04 to 1.08) and 1.05, respectively, and those for smoking were 1.95 (1.20 to 3.19) and 1.69, respectively. For women, the relative risks for diabetes mellitus were 5.40 (2.73 to 10.66) and 1.82, respectively. There was a tendency for the risk associated with cholesterol levels to be higher for transplant recipients, compared with the FHS population, but the risks associated with high-density lipoprotein cholesterol levels and BP appeared to be comparable. Independent of these and other risk factors, the adjusted risk of IHD for the transplant recipient population has decreased. Compared with the era before 1986, transplantation between 1986 and 1992 was associated with a lower relative risk of 0.60 (0.39 to 0.92); transplantation after 1992 was associated with an even lower relative risk of 0.27 (0.11 to 0.63) for IHD. Of concern was the fact that dihydropyridine calcium channel antagonists were associated with an increased risk for IHD (relative risk, 2.26; 95% confidence interval, 1.24 to 4.12; P = 0.008), and this association was independent of other antihypertensive agents and risk factors. Therefore, although the FHS risk predicts IHD after renal transplantation, it tends to underestimate the risks, especially the risk associated with diabetes mellitus. The unexpected finding that dihydropyridine calcium channel antagonists were associated with an increased IHD risk merits further evaluation.
- 10 May 2000
- Published by American Medical Association (AMA) in JAMA
- Vol. 283 (18) , 2445-50
Payment for Immunosuppression After Organ Transplantation
Dramatic improvements in organ transplantation have meant that a growing number of patients must take expensive immunosuppressive medications for the rest of their lives. Currently, Medicare covers most transplantation procedures in the United States, but ends coverage for outpatient immunosuppressive medications after 36 months. Evidence suggests that at least some patients have reduced immunosuppression and their transplants fail because they cannot afford these medication costs. In the years since the advent of effective immunosuppressive therapy, the US Congress has struggled with this issue, and in 1999 temporarily extended medication coverage for eligible patients (based on age and disability) by 8 months. However, a more permanent solution is needed. We advocate that Medicare should cover the cost of all immunosuppressive therapy for all solid organ transplant recipients who cannot afford to pay. A number of potentially cost-effective approaches could be taken, but, in any case, something must be done to ensure that transplants do not fail because recipients cannot pay for immunosuppression.
- 10 May 2000
- Published by American Medical Association (AMA) in JAMA
- Vol. 283 (18) , 2445-50
Payment for Immunosuppression After Organ Transplantation
Dramatic improvements in organ transplantation have meant that a growing number of patients must take expensive immunosuppressive medications for the rest of their lives. Currently, Medicare covers most transplantation procedures in the United States, but ends coverage for outpatient immunosuppressive medications after 36 months. Evidence suggests that at least some patients have reduced immunosuppression and their transplants fail because they cannot afford these medication costs. In the years since the advent of effective immunosuppressive therapy, the US Congress has struggled with this issue, and in 1999 temporarily extended medication coverage for eligible patients (based on age and disability) by 8 months. However, a more permanent solution is needed. We advocate that Medicare should cover the cost of all immunosuppressive therapy for all solid organ transplant recipients who cannot afford to pay. A number of potentially cost-effective approaches could be taken, but, in any case, something must be done to ensure that transplants do not fail because recipients cannot pay for immunosuppression.
- 1 April 2000
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 11 (4) , 753-759
Cigarette Smoking in Renal Transplant Recipients
: Cigarette smoking increases the risk for cancer and cardiovascular disease in the general population, but the effects of smoking in renal transplant recipients are unknown. The effects of smoking were investigated among patients transplanted at Hennepin County Medical Center between 1963 and 1997. Information on smoking was available in 1334 patients. The 24.7% prevalence of smoking at the time of transplantation was similar to that in the general population. After adjusting for multiple predictors of graft failure, smoking more than 25 pack-years at transplantation (compared to smoking less than 25 pack-years or never having smoked) was associated with a 30% higher risk of graft failure (relative risk 1.30; 95% confidence interval [CI], 1.04 to 1.63; P = 0.021). Having quit smoking more than 5 yr before transplantation reduced the relative risk of graft failure by 34% (relative risk 0.66; 95% CI, 0.52 to 0.85; P < 0.001). The increase in graft failure was due to an increase in deaths (adjusted relative risk 1.42; 95% CI, 1.08 to 1.87; P = 0.012). The relative risk for major cardiovascular disease events with smoking 11 to 25 pack-years at transplant was 1.56 (95% CI, 1.06 to 2.31; P = 0.024), whereas that of smoking more than 25 pack-years was 2.14 (95% CI, 1.49 to 3.08; P < 0.001). The relative risk of invasive malignancies was 1.91 (95% CI, 1.05 to 3.48; P = 0.032). Smoking had no discernible effect on the rate of return to dialysis or on serum creatinine during the first year after transplantation. Thus, cigarette smoking is associated with an increased risk of death after renal transplantation. The effects of smoking appear to dissipate 5 yr after quitting. These results indirectly suggest that greater efforts to encourage patients to quit smoking before transplantation may decrease morbidity and mortality.
- 1 April 2000
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 11 (4) , 753-759
Cigarette Smoking in Renal Transplant Recipients
: Cigarette smoking increases the risk for cancer and cardiovascular disease in the general population, but the effects of smoking in renal transplant recipients are unknown. The effects of smoking were investigated among patients transplanted at Hennepin County Medical Center between 1963 and 1997. Information on smoking was available in 1334 patients. The 24.7% prevalence of smoking at the time of transplantation was similar to that in the general population. After adjusting for multiple predictors of graft failure, smoking more than 25 pack-years at transplantation (compared to smoking less than 25 pack-years or never having smoked) was associated with a 30% higher risk of graft failure (relative risk 1.30; 95% confidence interval [CI], 1.04 to 1.63; P = 0.021). Having quit smoking more than 5 yr before transplantation reduced the relative risk of graft failure by 34% (relative risk 0.66; 95% CI, 0.52 to 0.85; P < 0.001). The increase in graft failure was due to an increase in deaths (adjusted relative risk 1.42; 95% CI, 1.08 to 1.87; P = 0.012). The relative risk for major cardiovascular disease events with smoking 11 to 25 pack-years at transplant was 1.56 (95% CI, 1.06 to 2.31; P = 0.024), whereas that of smoking more than 25 pack-years was 2.14 (95% CI, 1.49 to 3.08; P < 0.001). The relative risk of invasive malignancies was 1.91 (95% CI, 1.05 to 3.48; P = 0.032). Smoking had no discernible effect on the rate of return to dialysis or on serum creatinine during the first year after transplantation. Thus, cigarette smoking is associated with an increased risk of death after renal transplantation. The effects of smoking appear to dissipate 5 yr after quitting. These results indirectly suggest that greater efforts to encourage patients to quit smoking before transplantation may decrease morbidity and mortality.
- 1 July 1999
- Published by Elsevier in Kidney International
- Vol. 56, S28-S30
Role of circulating lipid abnormalities in chronic renal allograft rejection
- 1 July 1999
- Published by Elsevier in Kidney International
- Vol. 56, S28-S30
Role of circulating lipid abnormalities in chronic renal allograft rejection
- 1 July 1998
- Published by Wolters Kluwer Health in Transplantation
- Vol. 66 (2) , 209-214
SUCCESSFUL RENAL TRANSPLANTATION IN AMERICAN INDIANS
The incidence of end-stage renal disease is rapidly growing among American Indians, but there have been no detailed reports of outcomes after renal transplantation in this population. We compared the effects of race on risks and outcomes for renal transplants performed at a single center. There were 68 transplants in American Indians, 55 in African-Americans, 32 in Asians, 33 in other races, and 1253 in Caucasians (total=1441 transplants). American Indian transplant recipients had a high prevalence of risk factors. American Indians were more likely to be diabetic (45.6%) compared with African-Americans (21.8%), Asians (9.4%), other races (15.2%), and Caucasians (25.9%); overall P30 kg/m2) compared with African-Americans (12.7%), Asians(3.1%), other races (6.1%), and Caucasians (9.7%); overallP50% was higher for American Indian recipients (32.4%) compared with African-Americans (16.4%), Asians (21.9%), other races (27.3%) and Caucasians (15.6%); P<0.01. Despite these differences in risk, there were no statistically significant differences in the incidence of acute rejection, patient survival, or graft survival between American Indians and other racial groups in univariate survival analysis. In a Cox proportional hazards model that adjusted for multiple risk factors, graft survival was not different for American Indians (P=0.71), African-Americans (P=0.60), or other races (P=0.34) compared with Caucasians, whereas Asians were only 44% as likely to have graft failure (P=0.07). Patient survival was not different among races. Outcomes for renal transplantation are excellent for American Indians, despite a high prevalence of risk factors.
- 1 July 1998
- Published by Wolters Kluwer Health in Transplantation
- Vol. 66 (2) , 209-214
SUCCESSFUL RENAL TRANSPLANTATION IN AMERICAN INDIANS
The incidence of end-stage renal disease is rapidly growing among American Indians, but there have been no detailed reports of outcomes after renal transplantation in this population. We compared the effects of race on risks and outcomes for renal transplants performed at a single center. There were 68 transplants in American Indians, 55 in African-Americans, 32 in Asians, 33 in other races, and 1253 in Caucasians (total=1441 transplants). American Indian transplant recipients had a high prevalence of risk factors. American Indians were more likely to be diabetic (45.6%) compared with African-Americans (21.8%), Asians (9.4%), other races (15.2%), and Caucasians (25.9%); overall P30 kg/m2) compared with African-Americans (12.7%), Asians(3.1%), other races (6.1%), and Caucasians (9.7%); overallP50% was higher for American Indian recipients (32.4%) compared with African-Americans (16.4%), Asians (21.9%), other races (27.3%) and Caucasians (15.6%); P<0.01. Despite these differences in risk, there were no statistically significant differences in the incidence of acute rejection, patient survival, or graft survival between American Indians and other racial groups in univariate survival analysis. In a Cox proportional hazards model that adjusted for multiple risk factors, graft survival was not different for American Indians (P=0.71), African-Americans (P=0.60), or other races (P=0.34) compared with Caucasians, whereas Asians were only 44% as likely to have graft failure (P=0.07). Patient survival was not different among races. Outcomes for renal transplantation are excellent for American Indians, despite a high prevalence of risk factors.
- Open Access
- 1 April 1998
- Published by Elsevier in Kidney International
- Vol. 53 (4) , 819-825
Meta-analysis as a clinical tool in nephrology
- 1 April 1998
- Published by Elsevier in Kidney International
- Vol. 53 (4) , 819-825
Open AccessMeta-analysis as a clinical tool in nephrology
- 1 December 1997
- Vol. 63, S71-4
Clinical correlates to chronic renal allograft rejection.
Chronic rejection is a clinical syndrome characterized by a progressive decline in renal allograft function and nonspecific histologic findings of interstitial fibrosis, glomerulosclerosis, and fibrointimal proliferation of intrarenal arteries. Most late allograft failure that is not due to death with a functioning allograft is caused by chronic rejection. Although the pathogenesis and treatment of chronic rejection are unknown, a number of epidemiological studies have examined clinical correlates for possible clues to its pathogenesis. Clinical correlates for chronic renal allograft rejection can be classified in two broad categories: immune (alloantigen-dependent) and non-immune (alloantigen-independent). The strongest evidence that chronic rejection is immune mediated comes from its association with acute rejection and the degree of histocompatibility mismatching. However, not all acute rejection leads to chronic rejection, and there is little evidence that newer immunosuppression regimens which effectively prevent acute rejection have reduced the incidence and severity of chronic rejection. Therefore, many clinical investigators have also looked for potential non-immune causes of chronic rejection. Putative non-immune risk factors include donor source (living-related vs. cadaveric), cold ischemia time, delayed graft function, size mismatching, donor age, donor and recipient gender, recipient race, hyperlipidemia, and hypertension. Although there is little evidence supporting a cause and effect relationship between any immune or non-immune risk factor and chronic rejection, these clinical associations suggest a number of potentially important areas for further study.
- 1 December 1997
- Vol. 63, S71-4
Clinical correlates to chronic renal allograft rejection.
Chronic rejection is a clinical syndrome characterized by a progressive decline in renal allograft function and nonspecific histologic findings of interstitial fibrosis, glomerulosclerosis, and fibrointimal proliferation of intrarenal arteries. Most late allograft failure that is not due to death with a functioning allograft is caused by chronic rejection. Although the pathogenesis and treatment of chronic rejection are unknown, a number of epidemiological studies have examined clinical correlates for possible clues to its pathogenesis. Clinical correlates for chronic renal allograft rejection can be classified in two broad categories: immune (alloantigen-dependent) and non-immune (alloantigen-independent). The strongest evidence that chronic rejection is immune mediated comes from its association with acute rejection and the degree of histocompatibility mismatching. However, not all acute rejection leads to chronic rejection, and there is little evidence that newer immunosuppression regimens which effectively prevent acute rejection have reduced the incidence and severity of chronic rejection. Therefore, many clinical investigators have also looked for potential non-immune causes of chronic rejection. Putative non-immune risk factors include donor source (living-related vs. cadaveric), cold ischemia time, delayed graft function, size mismatching, donor age, donor and recipient gender, recipient race, hyperlipidemia, and hypertension. Although there is little evidence supporting a cause and effect relationship between any immune or non-immune risk factor and chronic rejection, these clinical associations suggest a number of potentially important areas for further study.